WATERTOWN, Mass. — September 3, 2025 — Leads & Copy — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) will share data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025, at 11:10 am ET in Toronto, Canada.
The presentation, titled “Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma,” will be presented by Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology.
C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, demonstrating a well-tolerated safety profile and compelling response rates. An investor webcast will be hosted on September 20, 2025, at 3 pm ET to highlight the data and provide additional detail on the company’s planned next steps of clinical development. A replay of the webcast will be archived and available following the event.
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives.
Cemsidomide is an investigational, orally bioavailable small-molecule degrader designed to be a more potent and selective degrader of IKZF1/3, transcription factors that drive multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), with unique pharmacokinetic properties. More information may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).
Contacts:
Investors: Courtney Solberg, Associate Director, Investor Relations, CSolberg@c4therapeutics.com
Media: Loraine Spreen, Senior Director, Corporate Communications & Patient Advocacy, LSpreen@c4therapeutics.com
Source: C4 Therapeutics
